Navigation Links
DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
Date:4/1/2008

Data supports potential use of DIO-902 with Atorvastatin

SAN FRANCISCO, April 1, 2008 /PRNewswire/ -- DiObex, Inc., a privately held biotechnology company focused on the development of therapeutics to treat metabolic diseases, announced today that a scientific poster relating to DIO-902 (levdexketoconazole) is being presented at the American Society for Clinical Pharmacology and Therapeutics annual meeting on Saturday, April 5th in Orlando. DIO-902 is being studied in Phase 2b clinical trials for the treatment of type 2 diabetes.

The poster, entitled "Differential Effects of Co-Administration of Racemic Ketoconazole and Levdexketoconazole on the Pharmacokinetic Profile of Atorvastatin," highlights the results of a study evaluating the effects of equal doses of the single enantiomer DIO-902 and racemic ketoconazole, on the pharmacokinetics of a single 80 mg dose of atorvastatin in healthy volunteers. Overall, repeated oral administration of DIO-902 tablets with atorvastatin was safe and well tolerated; in addition, DIO-902 significantly reduced cortisol levels compared with ketoconazole.

"The increase in total exposure of atorvastatin was significantly less when it was administered with DIO-902 than with racemic ketoconazole," said Dr. Tim Stewart, Vice President of Research at DiObex. "In addition, the administration of DIO-902 with atorvastatin resulted in significantly reduced cortisol levels from placebo, compared with atorvastatin administered with racemic ketoconazole. This finding supports preclinical evidence that DIO-902 is a more potent inhibitor of cortisol synthesis than ketoconazole."

DIO-902 is an oral, single enantiomer of ketoconazole, a common anti-fungal drug. DiObex is developing DIO-902 as a novel cortisol inhibitor for treating type 2 diabetes and diabetic nephropathy. There is growing evidence linking abnormal cortisol metabolism to both type 2 diabetes and metabolic syndrome, prompting a search for therapeutic agents that lower levels of cortisol or block the effects of cortisol excess. Preclinical and clinical data indicate that DIO-902 is a potent cortisol inhibitor. Clinical data also show early trends toward reductions in HbA1c, total cholesterol, LDL cholesterol, and C-reactive protein. Preclinical and clinical data also suggest that DIO-902 may be a safer and more effective agent than racemic ketoconazole.

About DiObex

DiObex, Inc. is a privately held biotechnology company developing novel products for diabetes and metabolic diseases. DiObex has two product candidates in four mid-stage clinical development programs. DIO-901 (very low dose glucagon) is in development for the prevention of insulin-induced hypoglycemia in type 1 diabetes mellitus in an extended release subcutaneous formulation and in a convenient disposable subcutaneous delivery device. DIO-901 has received Fast Track status from the FDA. DIO-902 (levdexketoconazole) is an oral, single enantiomer of ketoconazole that is a novel cortisol synthesis inhibitor in development for type 2 diabetes mellitus and diabetic nephropathy. Abnormalities in cortisol activity may play an important role in the development of metabolic syndrome, a constellation of conditions that place people at high risk for type 2 diabetes mellitus and cardiovascular disease. For more information, visit http://www.diobex.com.


'/>"/>
SOURCE DiObex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. DiObex and Camurus Sign License Agreement for the Development of DIO-901 in FluidCrystal(R) Extended Release Technology
2. DiObex, Inc. to Present at Merrill Lynch Global Healthcare Conference
3. DiObex Inc. to Present at BIO Mid-America Venture Forum
4. DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
5. Human Pheromone Sciences Announces Quarterly and Full Year Results
6. Dragon Pharma announces 2007 full year financial results
7. Genaera Corporation Announces 2007 Financial Results
8. Genmab Announces Year End 2007 Financial Results
9. Immunosyn Corporation Announces 2007 Results, Files 10KSB
10. Elbit Imaging Ltd. Announces Results For Fiscal Year 2007
11. The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... May 31, 2016 , ... RURO, Inc., a leading ... minor release with several important advancements to ease data entry, enhance security, expand ... Limfinity® has become one of the most sought after options by large scale ...
(Date:5/31/2016)... ... May 31, 2016 , ... Scientists at two major cancer research centers ... survival as surgery patients who are younger. Surviving Mesothelioma has just published an article ... Doctors at Duke and Stanford Universities analyzed data from the Surveillance, Epidemiology, and End ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... ... and markets molecular imaging systems, today announced that their compact PET scanner called ... Resonance Imaging) has been selected by the University of Arizona (UA). , PET ...
(Date:5/27/2016)... ... 2016 , ... NeuMedics Inc. is pleased to announce that CEO Iain Duncan ... June 2, 2016. The session begins at 1:10 PM and Iain will present the ... used as a topical agent and a treatment for ophthalmic complications of diabetes. , ...
Breaking Biology Technology:
(Date:3/18/2016)... , March 18, 2016 --> ... of Biometrics, ICT, Manned & Unmanned Vehicles, Physical infrastructure and ... security companies in the border security market and the continuing ... and Europe has led visiongain to ... improved success. --> defence & security companies ...
(Date:3/14/2016)... 2016 http://www.apimages.com ) - ... - Renvoi : image disponible via AP Images ... --> DERMALOG, le leader de ... lecteurs d,empreintes digitales pour l,enregistrement des réfugiés en ... pour produire des cartes d,identité aux réfugiés. DERMALOG ...
(Date:3/9/2016)... This BCC Research report provides an overview ... Sequencing (RNA Seq) market for the years 2015, 2016 ... reagents, data analysis, and services. Use this ... market such as RNA-Sequencing tools and reagents, RNA-Sequencing data ... each segment and forecast their market growth, future trends ...
Breaking Biology News(10 mins):